Company profile: Allos Therapeutics
1.1 - Company Overview
Company description
- Provider of anti-cancer therapeutics, developing and commercializing treatments including FOLOTYN, a folate analogue metabolic inhibitor that accumulates in cancer cells to cause cell death. Also offers Causal AI to predict effects of clinical interventions for complex generics development, and Licensing & Pipeline co-development and drug licensing to make medications more accessible.
Products and services
- FOLOTYN: A clinical-grade folate analogue metabolic inhibitor engineered to preferentially accumulate in cancer cells, causing cell death as Allos Therapeutics’ main anti-cancer product
- Licensing & Pipeline: A regulatory-compliant service that architects co-development and licensing opportunities for drugs, expanding access to medications by enabling shared development pathways and licensed distribution
- Causal AI: A model-driven technology that leverages causal reasoning to predict effects of clinical interventions on patient outcomes, enhancing the development of complex generics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allos Therapeutics
Pharmacyclics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmacyclics company profile →
Aletheia Therapeutics
HQ: United States
Website
- Description: Provider of precision oncology therapeutics based in Fort Collins, Colorado, developing and commercializing clinical-stage cancer therapies that simultaneously target two or more of DNA repair, T-cell activation, and metabolic dysfunction, tailored to the make-up of a patient's cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aletheia Therapeutics company profile →
Complix
HQ: Belgium
Website
- Description: Provider of Alphabody biopharmaceuticals focused on discovering and developing a novel class of therapeutics that bind with high affinity to disease targets. Offerings include Cell Penetrating Alphabodies to modulate intracellular protein interactions, a pipeline for intracellular targets in cancer, autoimmunity, and viral diseases, and anti-Covid-19 Alphabodies targeting SARS-CoV-2 fusion for prophylactic and therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Complix company profile →
Aegera Therapeutics
HQ: Canada
Website
- Description: Provider of clinical-stage targeted therapeutics addressing major unmet medical needs, with three programs in clinical development—two in oncology and one in neuropathic pain—and ongoing identification of novel development candidates based on core technologies. Part of Pharmascience Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegera Therapeutics company profile →
ABK Biomedical
HQ: Canada
Website
- Description: Provider of biomaterials solutions for the clinical market, focused on improving treatment options for patients with hypervascular tumors and transforming embolization procedures in interventional radiology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ABK Biomedical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allos Therapeutics
2.2 - Growth funds investing in similar companies to Allos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allos Therapeutics
4.2 - Public trading comparable groups for Allos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →